TuHURA secures $50M credit facility from largest shareholder affiliate at 12% interest

Filed April 22, 2026 · Period ending April 21, 2026 · ~1 min read

Key Changes

• high

  Entered $50M revolving credit facility with Parkview Holdings (affiliate of largest shareholder), maturing 2031, bearing 12% interest (18% if default), secured by substantially all assets to fund clinical trials through Q1 2028.

  Item 1.01 verify on EDGAR →
• high

  Granted royalty on future IFx-2.0 product sales in low-to-mid single digits on up to $450M annual sales, lasting through patent expiration—creating long-term revenue sharing with related-party lender.

  Item 1.01: Royalty Agreement verify on EDGAR →
• high

  Agreed to $5M commitment fee (10% of facility) payable via 1.88M shares to Parkview, subject to shareholder approval by August 31, 2026; otherwise due in cash. Also extended 4.36M warrants to 2031.

  Item 1.01: Fee Letter verify on EDGAR →